SS-31 (Elamipretide) vs NAD+: what the research actually compares
A side-by-side look at what published and registered research has measured for SS-31 (elamipretide) and NAD+ — the models used, the endpoints recorded, and the questions neither body of work answers.
SS-31, also written as Szeto-Schiller 31 and known by the name elamipretide, is a synthetic tetrapeptide described in the literature as having alternating cationic and aromatic residues, with reported properties of mitochondrial inner membrane binding and oxidative stress reduction [4]. NAD+, or nicotinamide adenine dinucleotide, is a dinucleotide cofactor; the research literature indexed here approaches it chiefly through supplementation precursors and oral supplement formulations rather than as a directly administered research peptide [1][2].
The pathway family at the centre of the SS-31 work is mitochondrial — inner membrane lipid interaction, oxidative stress, and mitochondrial function — while the NAD+ work indexed here centres on whole-blood and tissue NAD+ level measurement and on clinical endpoints in conditions such as glaucoma, peripheral artery disease, and post-COVID syndrome [2][3][4][5][6][8].
Research Studies
SS-31 (Elamipretide) and radiation-induced cardiomyocyte senescence
One study evaluated the mitochondrial-targeted peptide SS-31 (elamipretide) for its effects on radiation-induced cell senescence in cardiomyoblast H9C2 cells and in human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) [3]. Exposure to γ-radiation at doses of 2, 5, and 10 Gy inhibited H9C2 cell proliferation in a dose-dependent manner and induced senescence-associated beta-galactosidase (SA-β-gal) staining [3]. The work was conducted in cell models, not in whole animals or humans.
SS-31 (Elamipretide) and α-synuclein membrane interaction
A separate study examined SS-31 in the context of α-synuclein, whose membrane binding and aggregation properties are closely associated with Parkinson's disease and a class of related syndromes termed synucleinopathy [4]. Using fluorescence correlation spectroscopy and fluorescence anisotropy, the investigators demonstrated that SS-31 displaces both wild-type and N-terminal acetylated α-synuclein, and the study addressed impairment of mitochondrial function induced by α-synuclein oligomers [4]. This is a biophysical and cell-level line of work.
SS-31 (Elamipretide) and mitochondrial targeting in aged female mice under nutritional stress
A comparative evaluation of MitoQ and SS-31 (elamipretide) was conducted in aged female mice under nutritional stress, in a model of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) [9]. The paper frames early mitochondrial dysfunction as a driver of lipid imbalance, inflammation, and fibrosis, and notes the absence of approved pharmacological treatments in that indication [9]. This is a reference item supporting the wider mitochondrial-targeting literature rather than a dedicated SS-31 study page.
NAD+ and whole-blood level measurement in healthy adults
A registered clinical trial is designed to assess the absorption, safety, and efficacy of an oral NAD+ supplement in healthy adults, with the primary question being the change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo [2]. Participants are asked to complete questionnaires, provide blood samples, consume either the supplement or a placebo for 55 days, and have endothelial function evaluated [2]. The comparison is supplement versus placebo in a healthy adult population.
NAD+ measurement methodology and nicotinamide riboside
A separate registered study aims to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the-counter nicotinamide riboside (NR), using magnetic resonance spectroscopy (MRS) [1]. The stated purpose is measurement validation for human clinical studies [1]. Note that this study concerns NR as the supplement, not NAD+ administered directly.
Nicotinamide and retinal nerve cell layer thinning in primary open-angle glaucoma
The NADIR trial is designed to learn whether high-dose nicotinamide, described as a vitamin B3 supplement, can protect retinal nerve cells in adults with primary open-angle glaucoma (POAG) who are already receiving standard glaucoma eye drops or laser treatment [5]. The primary question is whether adding nicotinamide to standard therapy slows the rate of thinning of the inner retinal nerve cell layer, measured by a non-invasive eye scan, compared to standard therapy alone over 12 months [5]. Participants are randomised to treatment or control, with the treatment group taking nicotinamide tablets by mouth starting at 1.5 grams per day [5].
Nicotinamide riboside and walking distance in peripheral artery disease
The NICE-PAD II trial tests the hypothesis that, among people with peripheral artery disease (PAD) aged 50 and older, participants randomised to nicotinamide riboside (NR) will show greater improvement or less decline in six-minute walk distance at six-month follow-up compared to placebo [6]. The study randomises 250 participants with PAD aged 50 and older to NR or placebo for six months [6]. The primary outcome is change in six-minute walk distance at six-month follow-up; secondary outcomes include Walking Impairment Questionnaire (WIQ) distance score, PROMIS Mobility score, and calf muscle perfusion measured by magnetic resonance arterial spin labelling [6].
Nicotinamide and post-COVID syndrome in patients with documented tryptophan deficiency
An observational study examines CICR-NAM, described as nicotinamide tablets formulated to release the active substance selectively in the lower intestine, as a food for special medicinal purposes in post-COVID syndrome (PCS) [8]. The rationale references changes in tryptophan metabolism, energy metabolism, and the gut microbiome in PCS, and an earlier nutritional study in which patients with COVID-19 recovered physical performance more quickly when taking nicotinamide, with responders developing post-COVID syndrome less frequently [8]. The population is patients with post-COVID syndrome and documented tryptophan deficiency [8].
Where the two bodies of work sit side by side
| Dimension | SS-31 (Elamipretide) | NAD+ (and its precursors) |
|---|---|---|
| Chemical class | Synthetic tetrapeptide with alternating cationic and aromatic residues [4] | Dinucleotide cofactor; indexed work uses oral supplement and precursor forms [1][2] |
| Central pathway in the indexed work | Mitochondrial inner membrane binding, oxidative stress, mitochondrial function [3][4] | NAD+ level measurement in blood and tissue; clinical endpoints in specific conditions [1][2][5][6] |
| Model types represented | Cell models (H9C2, hiPSC-CMs), biophysical assays, aged female mice [3][4][9] | Registered human trials in healthy adults and patient populations [1][2][5][6][8] |
| Primary endpoints recorded | Proliferation, SA-β-gal staining, α-synuclein displacement, mitochondrial function [3][4] | Whole-blood NAD+ change, retinal layer thinning, six-minute walk distance, symptom and mobility scores [2][5][6] |
| Populations studied | Cell lines and aged female mice [3][4][9] | Healthy adults; adults with POAG, PAD, or post-COVID syndrome [1][2][5][6][8] |
What the comparison does and does not establish
The two compounds are not studied against each other in any source indexed here. The SS-31 material is largely mechanistic and preclinical — cell senescence, protein-membrane interaction, and a comparative mouse study in MASLD [3][4][9]. The NAD+ material is largely clinical and measurement-oriented, with registered trials in healthy adults and defined patient populations [1][2][5][6][8]. Where the evidence is stronger for one, it is stronger in a different register: SS-31 has more direct mechanistic characterisation in the sources given, while the NAD+ sources provide randomised human designs with named primary endpoints. Neither body of work, as indexed here, reports a head-to-head outcome, a shared endpoint, or a common model. Questions such as relative potency, comparative tissue distribution, or interchangeability are simply not addressed by these sources.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing here is a recommendation for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Validation of NAD+ Measurements for Human Clinical Studies — https://clinicaltrials.gov/study/NCT07416786
- [2] A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults — https://clinicaltrials.gov/study/NCT07692633
- [3] Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence — https://europepmc.org/article/PMC/PMC13400571
- [4] Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function — https://pubmed.ncbi.nlm.nih.gov/42219795/
- [5] Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial) — https://clinicaltrials.gov/study/NCT07808333
- [6] The NICE-PAD II Trial — https://clinicaltrials.gov/study/NCT07782671
- [8] Observational Study With CICR-NAM as a Food for Special Medicinal Purposes in Post-COVID Syndrome (PCS) — https://clinicaltrials.gov/study/NCT07798570
- [9] Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress — https://pubmed.ncbi.nlm.nih.gov/42708867/